CRIS Current Research Information System

TERRAGNA, CAROLINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.681
NA - Nord America 4.645
EU - Europa 3.477
AF - Africa 364
SA - Sud America 222
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 13.396
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.588
CN - Cina 1.380
SG - Singapore 1.318
VN - Vietnam 1.050
IT - Italia 816
GB - Regno Unito 667
SE - Svezia 459
DE - Germania 452
HK - Hong Kong 333
IN - India 239
NL - Olanda 192
KR - Corea 173
RU - Federazione Russa 171
BR - Brasile 158
FR - Francia 142
IE - Irlanda 134
CI - Costa d'Avorio 127
UA - Ucraina 81
TG - Togo 78
FI - Finlandia 76
CH - Svizzera 61
ZA - Sudafrica 60
SC - Seychelles 55
JP - Giappone 50
EE - Estonia 44
AT - Austria 41
BG - Bulgaria 40
NG - Nigeria 36
CA - Canada 34
AR - Argentina 30
JO - Giordania 30
BE - Belgio 29
ID - Indonesia 27
PL - Polonia 23
IR - Iran 21
MX - Messico 15
BD - Bangladesh 13
ES - Italia 13
TR - Turchia 12
EC - Ecuador 10
CO - Colombia 9
RO - Romania 6
CZ - Repubblica Ceca 5
GR - Grecia 5
IQ - Iraq 5
LT - Lituania 5
CL - Cile 4
LB - Libano 4
PH - Filippine 4
SA - Arabia Saudita 4
TN - Tunisia 4
HR - Croazia 3
PY - Paraguay 3
RS - Serbia 3
SV - El Salvador 3
UY - Uruguay 3
UZ - Uzbekistan 3
AU - Australia 2
CY - Cipro 2
EU - Europa 2
IL - Israele 2
LU - Lussemburgo 2
MA - Marocco 2
NZ - Nuova Zelanda 2
PE - Perù 2
PT - Portogallo 2
TH - Thailandia 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AO - Angola 1
BO - Bolivia 1
BS - Bahamas 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
HU - Ungheria 1
KG - Kirghizistan 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MN - Mongolia 1
MY - Malesia 1
NC - Nuova Caledonia 1
PA - Panama 1
PK - Pakistan 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
VE - Venezuela 1
ZM - Zambia 1
Totale 13.396
Salva come PNG Salva come JPEG
Città #
Singapore 869
Ashburn 622
Southend 584
Chandler 475
Fairfield 379
Hefei 374
Hong Kong 331
Ho Chi Minh City 245
Dallas 214
Ann Arbor 212
Bologna 211
Beijing 190
Houston 178
Hanoi 177
Seoul 173
Seattle 161
Wilmington 161
Woodbridge 155
Dong Ket 151
Princeton 144
Dublin 134
Abidjan 127
Santa Clara 122
Cambridge 118
Boardman 109
New York 91
Lomé 78
Los Angeles 75
Bremen 66
Milan 62
Nanjing 62
Westminster 53
Helsinki 52
Munich 49
Padova 49
Bern 48
Tokyo 47
Hyderabad 45
Berlin 40
Sofia 39
Turin 39
Bengaluru 35
Jacksonville 34
Jinan 34
Shenyang 34
Frankfurt am Main 33
Redondo Beach 33
Buffalo 32
Abeokuta 31
Amman 30
Medford 30
Brussels 29
Haiphong 29
Rome 29
Fabriano 27
Tianjin 27
Redmond 26
Vienna 24
Guangzhou 23
Saint Petersburg 23
Redwood City 22
Falkenstein 20
Salsomaggiore Terme 20
San Diego 20
São Paulo 20
Zhengzhou 20
Amsterdam 19
Changsha 19
Nanchang 19
Toronto 19
Hebei 18
Biên Hòa 17
Jakarta 17
Nuremberg 17
Ha Long 16
Florence 15
Warsaw 15
Falls Church 14
Washington 14
Dearborn 13
Lappeenranta 13
Quận Bình Thạnh 13
Shanghai 13
Tongling 13
Wuhan 12
Brooklyn 11
Chicago 11
Haikou 11
Mülheim 11
Ninh Bình 11
Phoenix 11
Quận Một 11
Turku 11
Yubileyny 11
Da Nang 10
Des Moines 10
Hangzhou 10
San Francisco 10
Chengdu 9
Düsseldorf 9
Totale 8.649
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 663
Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. 239
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 236
BoBafit: A copy number clustering tool designed to refit and recalibrate the baseline region of tumors’ profiles 234
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 231
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 230
c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in Chronic Myelogenous Leukemia CD34+ hematopoietic progenitor cells 229
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 222
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 199
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 194
A 41-gene signature predicts complete response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) as induction therapy prior to autologous stem-cell transplantation (ASCT) in multiple myeloma (MM). 189
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 189
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 185
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 182
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 179
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. 178
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 175
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 173
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 171
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 171
Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients 169
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. 168
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 168
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 168
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. 165
A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM) 163
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. 162
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 159
P-383 A 16-gene signature reflecting tumor microenvironment predicts the risk of multiple myeloma patients treated by bortezomib-based therapies 153
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients 152
Gas1 and Kif27 genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients 152
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 152
GAS1 AND KIF27 GENES ARE STRONGLY UP-REGULATED BIOMARKERS OF HEDGEHOG INHIBITION (PF-04449913) ON LEUKEMIA STEM CELLS IN PHASE I ACUTE MYELOID LEUKEMIA AND CHRONIC MYELOID LEUKEMIA TREATED PATIENTS 150
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 150
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 150
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 149
Cap dependent translation contributes to resistance of myeloma cells to bortezomib 149
Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease. 148
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 148
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. 146
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 146
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 144
Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores the angiogenic homeostasis and suppresses tumor progression 144
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation 143
HIF-1a INHIBITION PROMOTES CELL CYCLE ARREST IN MULTIPLE MYELOMA 137
NEXT GENERATION SEQUENCING FOR MINIMAL RESIDUAL DISEASE MEASUREMENT IN THE DAILY CLINICAL MANAGEMENT OF PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IS FEASIBLE AND PROVIDES USEFUL CLINICAL DATA. 133
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 133
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 131
Association between genotypes and response to the treatment in a subset of previously untreated chronic myeloid leukemia patients enrolled into the TOPS trial. 131
Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. 130
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 129
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 128
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 128
Analysis of Bone Marrow Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Bcr-Abl Positive CML in Chronic Phase Treated with Nilotinib 126
SIRT regulates the molecular interaction between c-MYC and HIF-1 alpha in multiple myeloma 124
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant 124
PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients 123
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma 122
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation 122
Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4 120
Positive Selection and Transplantation of Autologous Highly Purified CD133+ Stem Cells in Resistant/Relapsed Chronic Lymphocytic Leukemia Patients Results in Rapid Hematopoietic Reconstitution without an Adequate Leukemic Cell Purging 119
Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma 118
VarianThinker: a classification method to confidently approach the mutation heterogeneity in Multiple Myeloma 117
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 115
PF-04449913 reverts multi drug resistance (MDR) by a strong down-regulation of ABCA2 and BCL2 on leukemia stem cells in phase I acute myeloid leukemia and chronic myeloid leukemia treated patients 115
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 112
Synergism through WEE1 and CHK1 inhibition in acute lymphoblastic leukemia 112
A Methodologically Updated De-Novo Extraction of Copy Number Signatures in Multiple Myeloma: Clinical Significance and Putative Aetiologies 110
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients 110
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets 108
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience 108
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients 108
Overexpression of FBP1 is Associated to High Sokal Risk in Chronic Myeloid Leukemia Patients. 105
New drugs to overcome meccanisms of resistance in Ph+ leukemia: Bosutinib 104
Multiple myeloma: disease response assessment 103
INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia 102
Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche 99
Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma 99
null 98
Molecular monitoring of acute myeloid leukemia associated with inv(16): Threshold of CBFβ/MYH11 transcript copy number above which relapse occurs and below which continuous complete remission is likely (multiple letters) [8] 98
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients 97
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma 96
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment 95
Unraveling the Role of Peroxisome Proliferator-Activated Receptor β/Δ (PPAR β/Δ) in Angiogenesis Associated with Multiple Myeloma 88
Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies 87
Gene expression profiling (gep) of myeloma (MM) cells to predict attainment near complete response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed MM 80
COMPARISON BETWEEN NGS IGH/TCR AND RT-PCR BCR::ABL1 MINIMAL RESIDUAL DISEASE IN PH+ ACUTE LYMPHOBLASTIC LEUKEMIA: A PRELIMINARY ANALYSIS 77
Proteasome inhibitors: Bortezomib in multiple myeloma 75
Primary pulmonary T-cell lymphoproliferative disorders with a limited-stage, low proliferative index, and unusual clinical behavior: two cases of a rare occurrence 72
Editorial: Risk factors in multiple myeloma identified before and during treatment: are we ready to personalize treatment? 70
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 70
OAB-057: Temporal-weight estimation of the copy number alterations of of 1384 Multiple Myeloma patients defines an ancestrality index impacting patients survival 60
Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC 54
The road to cure in multiple myeloma: Incorporation of novel agents into autologous stem cell transplantation 52
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 50
Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia 43
IMPLEMENTATION OF NEXT GENERATION SEQUENCING AS BEST TOOL FOR ROUTINE EVALUATION OF MINIMAL RESIDUAL DISEASE IN THE DAILY PRACTICE OF MULTIPLE MYELOMA PATIENTS 42
Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia-positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24-homology domains but not the pleckstrin homology one 31
Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphoma 29
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies? 24
Totale 13.660
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.371
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.371
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021752 0 0 0 0 0 46 36 67 99 48 67 389
2021/20221.469 105 67 64 107 136 85 32 103 69 171 237 293
2022/20232.017 194 291 83 303 151 151 65 105 304 65 161 144
2023/2024770 58 83 64 61 59 174 46 111 19 32 30 33
2024/20252.505 155 260 199 198 257 110 197 90 42 248 184 565
2025/20263.785 584 1.221 584 508 613 275 0 0 0 0 0 0
Totale 13.687